Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹424 Cr.
Stock P/E
25.6
P/B
3.5
Current Price
₹181
Book Value
₹ 52.1
Face Value
10
52W High
₹205.1
52W Low
₹ 111
Dividend Yield
0%

Mahamaya Lifescience Overview

Business

Mahamaya Lifesciences Ltd. is an Indian company primarily engaged in the manufacturing, formulation, and marketing of agrochemical products. The company offers a diverse range of crop protection chemicals, including insecticides, herbicides, fungicides, plant growth regulators (PGRs), and micronutrients. Its core business model revolves around developing these formulations and distributing them to the agricultural sector, predominantly farmers, across various states in India through a network of dealers and distributors. The company generates revenue by selling these agrochemicals, which are crucial for protecting crops from pests, diseases, and weeds, thereby enhancing agricultural yield and quality.

Revenue Mix

While specific revenue breakdowns are not widely published for Mahamaya Lifesciences Ltd., the company's product portfolio indicates a revenue mix generally spread across the following key agrochemical categories:

Insecticides: Products designed to control insect pests.

Herbicides: Products used to control weeds.

Fungicides: Products aimed at preventing and controlling fungal diseases in crops.

Plant Growth Regulators & Micronutrients: Products that promote healthy plant growth and address nutrient deficiencies.

Revenue contribution from each segment would depend on market demand, product launch cycles, and regional agricultural practices.

Industry

The Indian Pesticides & Agrochemicals industry is a significant and growing sector, driven by the country's vast agricultural landscape and the continuous need for food security. It comprises both large multinational corporations and numerous domestic players. Mahamaya Lifesciences Ltd. operates as a participant in this competitive market, likely focusing on specific regions or product formulations to carve out its niche. It competes with established larger domestic players (e.g., UPL, PI Industries, Rallis India) as well as other mid-to-small-sized regional players. Its positioning would be influenced by its distribution reach, product effectiveness, and pricing strategies in its target markets.

MOAT

Mahamaya Lifesciences Ltd. does not appear to possess a wide, durable competitive moat often associated with market leaders. As a formulator of generic agrochemicals, its advantages are likely derived from:

Distribution Network: An established dealer and distributor network in its operational regions, fostering farmer relationships.

Cost Efficiency: Efficient manufacturing and formulation processes to offer competitively priced products.

Product Efficacy: Developing effective formulations tailored to local crop protection needs.

Local Market Understanding: Knowledge of regional crop patterns, pest issues, and farmer preferences.

It does not typically benefit from strong intellectual property on novel molecules (as that is capital intensive R&D), dominant brand equity nationwide, or significant scale advantages over larger competitors.

Growth Drivers

Key factors that could drive growth for Mahamaya Lifesciences over the next 3-5 years include:

Agricultural Sector Growth: Overall expansion and modernization of Indian agriculture, leading to increased demand for inputs.

Increased Crop Intensity & Area: Growth in cultivated land area and adoption of multiple cropping cycles.

Pest & Disease Pressure: Persistent threat of pests, weeds, and diseases requiring effective agrochemical solutions.

Farmer Awareness: Growing farmer education and adoption of best agricultural practices, including the use of quality agrochemicals.

Government Initiatives: Policies supporting agricultural productivity, farm mechanization, and irrigation.

New Product Formulations: Expansion of its product portfolio to address a wider range of crops and specific agricultural challenges.

Risks

Monsoon Dependency: Indian agriculture is heavily reliant on monsoon patterns; poor monsoons can significantly reduce demand for agrochemicals.

Raw Material Price Volatility: Fluctuations in the prices of key chemical intermediates and crude oil derivatives can impact production costs and profitability.

Intense Competition: The agrochemical market is highly competitive, leading to potential pricing pressure and challenges in maintaining market share.

Regulatory Changes: Stringent environmental regulations, changes in product registration processes, or bans on certain chemicals can impact operations.

Seasonality: The business is cyclical and seasonal, tied directly to cropping patterns and agricultural cycles.

Counterfeit Products: The presence of counterfeit or substandard products in the market can erode trust and market share.

Management & Ownership

Mahamaya Lifesciences Ltd. is typically a promoter-driven company, common in the Indian SME landscape. Key individuals like Mr. Mahavir Prasad Agarwal, Mr. Mukesh Agarwal, and Mr. Sanjay Agarwal are associated with the management and promoter group, indicating an experienced leadership team within the sector. Promoter holding is generally significant in such companies, providing stability and aligning interests, though it also implies a concentrated ownership structure. Detailed assessment of management quality beyond this requires deeper insight into strategic execution and corporate governance records.

Outlook

Mahamaya Lifesciences operates in a fundamental sector with long-term demand drivers stemming from India's need for food security and increasing agricultural productivity. The company stands to benefit from continued growth in the Indian agricultural sector, increasing farmer awareness, and the ongoing need for crop protection. Its established distribution network and focus on a diverse portfolio of formulations provide a base for operations.

However, the company faces significant challenges typical of the agrochemical industry, including high dependency on erratic monsoon patterns, intense competition from larger domestic and international players, and susceptibility to volatile raw material prices. Regulatory changes and environmental concerns also pose ongoing risks. Its ability to grow sustainably will depend on its capacity to efficiently manage costs, effectively navigate competitive pressures, innovate with new formulations, and expand its market reach while adapting to agricultural and environmental policy shifts.

Mahamaya Lifescience Share Price

Live · BSE · Inception: 2016
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Mahamaya Lifescience Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Mahamaya Lifescience Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 90 137 162 266 329
Other Income 0 0 1 1 1
Total Income 90 137 163 267 330
Total Expenditure 84 128 148 241 295
Operating Profit 7 9 15 26 35
Interest 2 3 6 7 9
Depreciation 1 1 1 2 2
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax 4 5 7 17 24
Provision for Tax 1 1 2 4 7
Profit After Tax 3 4 5 13 17
Adjustments 0 0 0 0 0
Profit After Adjustments 3 4 5 13 17
Adjusted Earnings Per Share 2 2.7 3.8 7.2 7.1

Mahamaya Lifescience Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 16 19 25 49 122
Minority's Interest 0 0 0 0 0
Borrowings 10 10 9 6 4
Other Non-Current Liabilities 0 0 1 1 2
Total Current Liabilities 30 48 78 132 183
Total Liabilities 56 78 112 188 310
Fixed Assets 18 20 20 27 35
Other Non-Current Assets 4 4 4 5 9
Total Current Assets 33 54 87 157 266
Total Assets 56 78 112 188 310

Mahamaya Lifescience Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 1 1 3 4
Cash Flow from Operating Activities 2 1 -23 -0 -30
Cash Flow from Investing Activities -3 -3 -2 -7 -16
Cash Flow from Financing Activities 1 2 24 9 81
Net Cash Inflow / Outflow 0 1 -0 1 35
Closing Cash & Cash Equivalent 1 1 1 4 39

Mahamaya Lifescience Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 1.98 2.73 3.8 7.21 7.06
CEPS(Rs) 2.68 3.66 4.88 8.21 8.02
DPS(Rs) 0 0 0 0 0
Book NAV/Share(Rs) 11.43 14.15 17.95 27.82 52.1
Core EBITDA Margin(%) 7.05 6.66 8.34 9.3 10.31
EBIT Margin(%) 6.25 5.97 8.2 9.17 9.86
Pre Tax Margin(%) 4.14 3.72 4.41 6.49 7.25
PAT Margin (%) 3.03 2.74 3.23 4.82 5.02
Cash Profit Margin (%) 4.1 3.66 4.15 5.49 5.7
ROA(%) 4.9 5.62 5.49 8.53 6.63
ROE(%) 17.34 21.34 23.67 34.59 19.29
ROCE(%) 16.12 20.81 21.52 26.09 20.27
Receivable days 36.97 24.81 42.74 52.72 66.08
Inventory Days 75.64 71.11 96.92 103.86 133.71
Payable days 82.67 69.44 67.49 64.91 81.97
PER(x) 0 0 0 0 21.32
Price/Book(x) 0 0 0 0 2.89
Dividend Yield(%) 0 0 0 0 0
EV/Net Sales(x) 0.21 0.16 0.33 0.27 1.23
EV/Core EBITDA(x) 2.89 2.39 3.59 2.75 11.63
Net Sales Growth(%) 0 52.45 17.87 64.48 23.91
EBIT Growth(%) 0 45.57 61.81 84.01 33.18
PAT Growth(%) 0 37.72 39.14 145.5 28.97
EPS Growth(%) 0 37.72 39.14 89.82 -2.1
Debt/Equity(x) 1.22 1.25 2.22 1.18 0.74
Current Ratio(x) 1.11 1.13 1.12 1.19 1.45
Quick Ratio(x) 0.5 0.41 0.47 0.44 0.69
Interest Cover(x) 2.96 2.65 2.16 3.42 3.78
Total Debt/Mcap(x) 0 0 0 0 0.26

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +24% +34% — —
Operating Profit CAGR +35% +57% — —
PAT CAGR +31% +62% — —
Share Price CAGR — — — —
ROE Average +19% +26% +23% +23%
ROCE Average +20% +23% +21% +21%

Mahamaya Lifescience Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 56.35 %
FII 4.77 %
DII (MF + Insurance) 2.52 %
Public (retail) 36.36 %
# Sep 2025 Nov 2025 Mar 2026
Promoter 56.3556.3556.35
FII 6.396.394.77
DII 4.674.672.52
Public 32.5932.5936.36
Others 000
Total 100100100

Mahamaya Lifescience Peer Comparison

Pesticides & Agrochemicals Edit Columns

Mahamaya Lifescience Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Mahamaya Lifescience Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 26%
  • Company has reduced debt.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend.
  • Debtor days have increased from 64.91 to 81.97days.
  • Stock is trading at 3.5 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp